Clinical Trial Update: Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on LEZ763 evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LEZ763

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type II Diabetes | Phase 1, Phase 2 | Status: COMPLETED